Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pegfilgrastim Biosimilars in US Supportive Oncology: A Narrative Review of Administration Options and Economic Considerations to Maximize Patient Benefit

Pegfilgrastim Biosimilars in US Supportive Oncology: A Narrative Review of Administration Options... Granulocyte colony-stimulating factor (G-CSF) biologics, such as pegfilgrastim, are a standard of care in supportive cancer treatment that are administered once per chemotherapy cycle to reduce the incidence of febrile neutropenia. The high cost of these biologics in the United States can be a limiting factor to accessing care; however, lower-cost pegfilgrastim biosimilars have been available for several years for patients requiring prophylaxis of febrile neutropenia. Different options for pegfilgrastim administration are also now available to accommodate specific patient preferences. As patients may want to minimize the risk of both neutropenia and SARS-CoV-2 infection, same-day administration is a pertinent option during the present COVID-19 pandemic. Therefore, individualized, patient-centered approaches and risk-management strategies should be considered when selecting the treatment and administration method for prophylaxis of febrile neutropenia. Three methods of administration would minimize hospital or clinic visits while also providing the prophylactic effect of G-CSF: same-day administration after chemotherapy, use of the US Food and Drug Administration–approved on-body injector delivering pegfilgrastim approximately 27 h after chemotherapy, or self-administration by the patient or caregiver > 24 h after chemotherapy. Choice of the specific administration option should be based on the patient’s specific needs, while also considering mitigating factors, such as the economic burden associated with biologic medications and the risk of COVID-19. Pegfilgrastim biosimilars can minimize the additional financial burden on patients and the health care system during this pandemic and beyond. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Pegfilgrastim Biosimilars in US Supportive Oncology: A Narrative Review of Administration Options and Economic Considerations to Maximize Patient Benefit

Download PDF
11 pages

Loading next page...
 
/lp/springer-journals/pegfilgrastim-biosimilars-in-us-supportive-oncology-a-narrative-review-njmFtzgXin
Publisher
Springer Journals
Copyright
Copyright © The Author(s) 2022
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-022-00207-2
Publisher site
See Article on Publisher Site

Abstract

Granulocyte colony-stimulating factor (G-CSF) biologics, such as pegfilgrastim, are a standard of care in supportive cancer treatment that are administered once per chemotherapy cycle to reduce the incidence of febrile neutropenia. The high cost of these biologics in the United States can be a limiting factor to accessing care; however, lower-cost pegfilgrastim biosimilars have been available for several years for patients requiring prophylaxis of febrile neutropenia. Different options for pegfilgrastim administration are also now available to accommodate specific patient preferences. As patients may want to minimize the risk of both neutropenia and SARS-CoV-2 infection, same-day administration is a pertinent option during the present COVID-19 pandemic. Therefore, individualized, patient-centered approaches and risk-management strategies should be considered when selecting the treatment and administration method for prophylaxis of febrile neutropenia. Three methods of administration would minimize hospital or clinic visits while also providing the prophylactic effect of G-CSF: same-day administration after chemotherapy, use of the US Food and Drug Administration–approved on-body injector delivering pegfilgrastim approximately 27 h after chemotherapy, or self-administration by the patient or caregiver > 24 h after chemotherapy. Choice of the specific administration option should be based on the patient’s specific needs, while also considering mitigating factors, such as the economic burden associated with biologic medications and the risk of COVID-19. Pegfilgrastim biosimilars can minimize the additional financial burden on patients and the health care system during this pandemic and beyond.

Journal

Oncology and Therapy – Springer Journals

Published: Dec 1, 2022

Keywords: Biologic; Biosimilar; Cost-effectiveness; Formulary management; Oncology; Pegfilgrastim; Supportive care; Utilization management

References

  • Management of febrile neutropaenia: ESMO clinical practice guidelines
    Klastersky, J; de Naurois, J; Rolston, K; Rapoport, B; Maschmeyer, G; Aapro, M
  • The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials
    Wang, L; Baser, O; Kutikova, L; Page, JH; Barron, R
  • Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012
    Tai, E; Guy, GP; Dunbar, A; Richardson, LC
  • 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
    Aapro, MS; Bohlius, J; Cameron, DA; Dal Lago, L; Donnelly, JP; Kearney, N
  • Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)
    Gascón, P; Aapro, M; Ludwig, H; Bokemeyer, C; Boccadoro, M; Turner, M
  • Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?
    Weycker, D; Hackett, J; Edelsberg, JS; Oster, G; Glass, AG
  • Design rationale and development approach for pegfilgrastim as a long-acting granulocyte colony-stimulating factor
    Arvedson, T; O'Kelly, J; Yang, BB
  • Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects
    Roskos, LK; Lum, P; Lockbaum, P; Schwab, G; Yang, BB
  • Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)
    Naeim, A; Henk, HJ; Becker, L; Chia, V; Badre, S; Li, X
  • Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment
    Weycker, D; Bensink, M; Lonshteyn, A; Doroff, R; Chandler, D
  • Systematic review and meta-analysis of short- versus long-acting granulocyte colony-stimulating factors for reduction of chemotherapy-induced febrile neutropenia
    Cornes, P; Gascon, P; Chan, S; Hameed, K; Mitchell, CR; Field, P
  • Biosimilar pegfilgrastim: improving access and optimising practice to supportive care that enables cure
    Cornes, P; Gascon, P; Vulto, AG; Aapro, M
  • Revisiting same-day administration of pegfilgrastim in the age of biosimilars: a review of literature
    Gerberich, AJ; Attilio, MR; Svoboda, A
  • Cost savings of biosimilar pegfilgrastim in a Medicare OCM population
    Webster, J; Smith, RE; Wieland, D; Verniero, J; Scott, JA
  • Evolution of the EU biosimilar framework: past and future
    Wolff-Holz, E; Tiitso, K; Vleminckx, C; Weise, M
  • Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv
    MacDonald, K; McBride, A; Alrawashdh, N; Abraham, I
  • Simulation modeling of cost-savings from conversion of pegfilgrastim to biosimilar pegfilgrastim-cbqv for the prophylaxis of chemotherapy-induced (febrile) neutropenia (CIN/FN) and expanded access to biosimilar prophylaxis
    McBride, A; MacDonald, K; Abraham, I
  • Simulation modeling of budget-neutral expanded access to antineoplastic therapy from cost-savings derived from conversion to biosimilar pegfilgrastim-cbqv for the prophylaxis of chemotherapy-induced (febrile) neutropenia (CIN/FN) in early-stage breast cancer
    McBride, A; MacDonald, K; Abraham, I
  • A systematic review of financial toxicity among cancer survivors: we can't pay the co-pay
    Gordon, LG; Merollini, KMD; Lowe, A; Chan, RJ
  • Forgoing medical care because of cost: assessing disparities in healthcare access among cancer survivors living in the United States
    Weaver, KE; Rowland, JH; Bellizzi, KM; Aziz, NM
  • Impact of financial burden of cancer on survivors' quality of life
    Fenn, KM; Evans, SB; McCorkle, R
  • Clinical experience with Zarzio® in Europe: what have we learned?
    Gascón, P; Tesch, H; Verpoort, K
  • Promoting biosimilar competition by revising Medicare reimbursement rules
    Rome, BN; Sarpatwari, A
  • Administration options for pegfilgrastim prophylaxis: patient and physician preferences from a cross-sectional survey
    Hauber, BA; Mange, B; Price, MA
  • ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study
    Boeru, G; Milanov, I; De Robertis, F
  • How to help patients achieve correct self-injection technique
    Diggle, J; Phillips, A
  • Anaemia management in chronic kidney disease patients
    Pagels, AA; Hylander, B
  • Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe
    Yang, BB; Morrow, PK; Wu, X; Moxness, M; Padhi, D
  • Performance of the pegfilgrastim on-body injector as studied with placebo buffer in healthy volunteers
    Joshi, RS; Egbuna, OI; Cairns, AS
  • Retrospective review of pegfilgrastim on-body injector delivery rates in a large health system
    Stuessy, P; Sanchez, FA; Schober, M
  • On-body injector: an administration device for pegfilgrastim
    Mahler, LJ; DiBlasi, R; Perez, A; Gaspard, J; McCauley, D
  • Comparing grade 4 neutropenia associated with pegfilgrastim administered via the Onpro Device versus manual injection with a prefilled syringe
    Townley, C; Porter, C; McMullen, N
  • Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma
    McBride, A; Krendyukov, A; Mathieson, N
  • Ethnic differences in pegfilgrastim Onpro kit (on-body injector) use among cancer patients
    Relias, R; Hackenyos, DW; Wasif, K; Healey, P; Smith, MH; Saif, WM
  • Incidence of neutropenic fever at a safety net hospital in cancer chemotherapy patients receiving prophylactic pegfilgrastim manual injection compared to the on-body auto-injector
    Jindal, A; Kover, J; Raduka, V; O'Brien, TE
  • Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors
    Rowinsky, EK; Grochow, IB; Sartorius, SE
  • Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy
    Meropol, NJ; Miller, LL; Korn, EL
  • Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015
    Weycker, D; Bensink, M; Lonshteyn, A; Doroff, R; CHandler D.
  • Efficacy of same-day vs. next-day pegfilgrastim for the prevention of chemotherapy-induced (febrile) neutropenia (CIN/FN): a meta-analysis
    Diri, R; Diri, R; McBride, A
  • Outcomes of pegfilgrastim (PFG) administration on the same day vs the day after chemotherapy (CTX) in the prophylaxis of chemotherapy-induced (Febrile) neutropenia (CIN/FN): systematic review and meta-analysis
    AlRawashdh, N; McBride, A; Lee, C
  • A single-arm, retrospective analysis of the incidence of febrile neutropenia using same-day versus next-day pegfilgrastim in patients with gastrointestinal cancers treated with FOLFOX or FOLFIRI
    Eckstrom, J; Bartels, T; Abraham, I
  • Retrospective evaluation of safety and effectiveness of same-day pegfilgrastim in patients with lung cancer
    Alrawashdh, N; Vraney, J; Choi, BM; Almutairi, AR; Abraham, I; McBride, A
  • A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: an international collaborative group
    Al-Shamsi, HO; Alhazzani, W; Alhuraiji, A
  • Impact of hospital strain on excess deaths during the COVID-19 pandemic—United States, July 2020–July 2021
    French, G; Hulse, M; Nguyen, D
  • Economic impact of COVID-19 pandemic on healthcare facilities and systems: international perspectives
    Kaye, AD; Okeagu, CN; Pham, AD
  • Inpatient hospital costs for COVID-19 patients in the United States
    Ohsfeldt, RL; Choong, CKC; Mc Collam, PL; Abedtash, H; Kelton, KA; Burge, R